Artelo Biosciences, Inc. (ARTL)

Market Cap	3.06M
Revenue (ttm)	n/a
Net Income (ttm)	-9.12M
Shares Out	3.23M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,731
Open	0.940
Previous Close	0.932
Day's Range	0.910 - 0.950
52-Week Range	0.910 - 1.750
Beta	1.27
Analysts	Strong Buy
Price Target	5.50 (+480.41%)
Earnings Date	Nov 12, 2024

About ARTL

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indication...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: ARTL
• Website: https://www.artelobio.com

Analyst Forecast

According to 2 analysts, the average rating for ARTL stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 480.41% from the latest price.

Price Target

$5.5

(480.41% upside)

Analyst Consensus: Strong Buy